Tripsovyn

Tripsovyn is a preclinical-stage biotechnology company and a portfolio company of Genovyn, dedicated to developing novel therapeutics for Triple-Negative Breast Cancer (TNBC). The company's pipeline features three novel small molecules (TXP02, TXP03, and TXP04) and four unique drug combinations (TRIV-01 through TRIV-04) designed to operate independently of traditional hormone or HER2 receptor pathways. In tandem with its therapeutic pipeline, Tripsovyn is developing a companion diagnostic (CDx) to match patients with the most effective treatment based on their unique biology. By leveraging Genovyn's AI-enabled discovery platform, Tripsovyn aims to accelerate target identification and optimize treatment pathways. The company's business strategy centers on completing preclinical development and advancing candidates through Phase 1 clinical trials before seeking pharmaceutical partners for late-stage development and commercialization.